Lv11
22 积分 2022-01-24 加入
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
1小时前
待确认
Routes to molecular glue degrader discovery
1个月前
已完结
The Expanding E3 Ligase-Ligand Landscape for PROTAC Technology
1个月前
已完结
A mechanistic pharmacokinetic-pharmacodynamic model for degrader-antibody conjugates
1个月前
已完结
Rational engineering of degradation tail-driven CELMoD–antibody conjugates for precision malignancy therapy
1个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
3个月前
已完结
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
7个月前
已完结
A Patient-Derived Organoid Screen Identified the Bispecific Antibody MCLA-158
7个月前
已完结
NOP Receptor Signaling Cascades
11个月前
已完结
β−Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives
11个月前
已完结
皖公网安备34019202002308
